Abstract
Objective: Resting-state functional magnetic resonance imaging (rs-fMRI) at ultra high-field strengths (≥7T) is known to provide superior signal-to-noise and statistical power than comparable acquisitions at lower field strengths. In this study, we aim to provide a direct comparison of the seizure onset-zone (SOZ) lateralizing ability of 7T rs-fMRI and 3T rs-fMRI.
Methods: We investigated a cohort of 70 temporal lobe epilepsy (TLE) patients. A paired cohort of 19 patients had 3T and 7T rs-fMRI acquisitions for direct comparison between the two field strengths. Forty-three patients had only 3T, and 8 patients had only 7T rs-fMRI acquisitions. We quantified the functional connectivity between the hippocampus and other nodes within the default mode network (DMN) using seed-to-voxel connectivity, and measured how hippocampo-DMN connectivity could inform SOZ lateralization at 7T and 3T field strengths.
Results: Differences between hippocampo-DMN connectivity ipsilateral and contralateral to the SOZ were significantly higher at 7T (pFDR=0.008) than at 3T (pFDR=0.80) when measured in the same subjects. We found that our ability to lateralize the SOZ, by distinguishing subjects with left TLE from subjects with right TLE, was superior at 7T (AUC = 0.97) than 3T (AUC = 0.68). Our findings were reproduced in extended cohorts of subjects scanned at either 3T or 7T. Our rs-fMRI findings at 7T, but not 3T, are consistent and highly correlated (Spearman Rho=0.65) with clinical FDG-PET lateralizing hypometabolism.
Significance: We show superior SOZ lateralization in TLE patients when using 7T relative to 3T rs-fMRI, supporting the adoption of high-field strength functional imaging in the epilepsy presurgical evaluation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AL and KAD received support from NINDS (R01NS116504). NS received support from American Epilepsy Society (953257) and NINDS (R01NS116504).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data acquisition for this study was approved by the institutional review board of the University of Pennsylvania.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The processed paired 3T and 7T neuroimaging data and methodological pipeline used in this study will be made available on a public data repository (OSF) upon publication of the manuscript. The repository will be made publicly accessible to ensure that the data and methods used in this study can be transparently and independently verified.
